Merck & Co's Gefapixant Effective In Refractory Cough, But Taste Concerns Remain
Data From Phase III Studies To Be Shared With Regulators
Updated results from two Merck & Co Phase III studies, COUGH-1 and COUGH-2, confirm the drug’s efficacy in reducing the frequency of refractory cough and its association with taste disturbances.
